Can I read Vemurafenib in the Target Therapy of Metastatic Melanoma on EtoBox?

Vemurafenib in the Target Therapy of Metastatic Melanoma by Ivo Kocák, Ilona Kocáková, Stanislav Špelda is a scholarly article available to read on EtoBox.

What is Vemurafenib in the Target Therapy of Metastatic Melanoma about?

Metastatic melanoma is an aggressive disease. Historical treatment options have been limited (e.g. dacarbazine, temozolomide, high dose interleukin-2) and associated with poor outcomes. Vemurafenib is a first-in-class, small molecule BRAFV600 inhibitor. Vemurafenib is approved in the EU as monotherapy in adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma. In the trial BRIM-2 a BRIM-3 vemurafenib significantly improved both overall survival (OS) and progression free survival (PFS) in patients with unresectable melanoma.

Author

Ivo Kocák, Ilona Kocáková, Stanislav Špelda

Published

2013